Home > Insider Trading > Filing (0001179110-20-008396)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235010	Momenta Pharmaceuticals Inc	MNTA	Biological Products, (No Disgnostic Substances) (2836)	043561634

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1716468	M. Anthony Manning	C/O Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-07-17	3,500	$0.00	32,691	No	4	M	Direct
Common Stock	Acquisiton	2020-07-20	33,125	$12.76	65,816	No	4	M	Direct
Common Stock	Disposition	2020-07-20	1,561	$33.95	64,255	No	4	S	Direct
Common Stock	Disposition	2020-07-20	49,538	$33.91	14,717	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2020-07-17	3,500	$0.00	3,500	$0.00
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-20	33,125	$0.00	33,125	$12.76

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
31,500			No	4	M	Direct
52,793	2020-05-11	2029-02-11	No	4	M	Direct

Footnotes

Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018.
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
Restricted Stock Units convert into common stock on a one-for-one basis.
This transaction was executed in multiple trades at prices ranging from $33.22 to $34.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.